Peptides: Miracle or Marketing?

The global peptide supplement market hit $4.1 billion in 2025 and is projected to reach $11.2 billion by 2035. Instagram influencers, Silicon Valley biohackers, and MAHA movement figures are all talking about them. Your patients are asking about them constantly. And the regulatory landscape just changed dramatically — in April 2026, RFK Jr. announced the removal of 12 peptides including BPC-157, TB-500, and GHK-Cu from the FDA's restricted Category 2 list, with an advisory panel convening in July 2026 to formally consider adding them back to the legal compounding list.This episode is the honest, physician-level answer to a question patients ask every week: are peptides real medicine or expensive hope? Dr. Chris Lee goes compound by compound — what the science actually says, what he personally uses and prescribes, what he wouldn't touch, and what the regulatory situation actually means for patients trying to access them safely. From BPC-157 and TB-500 for healing and recovery, to the tesamorelin/ipamorelin GH stack, to sermorelin, to GHK-Cu for skin and tissue remodeling, to the GLP-1s as the most successful peptides in history — this is the unfiltered, clinical version of the peptide conversation. Chris is currently using the tesamorelin/ipamorelin stack himself and shares his real early results including measurable improvements in deep sleep, overnight sleep continuity, workout recovery, and HRV.The honest answer is nuanced: some of these compounds have real, compelling evidence. Some are mostly hype. Some sit in a fascinating gray zone where the anecdotal signal is strong but the clinical trials don't yet exist. And the regulatory picture — which just shifted significantly — means that access and legality are both moving targets right now. Chris explains exactly where everything stands as of today.